Nkarta
CompanyUnited States
Nkarta develops one asset, in phase 1 (NKX101 in adult aml). Mostly cell therapy; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 1
- 1
- Trial
- 1
- Signal
Pipeline
1Engineered natural killer cells recognize NKG2D ligands on malignant cells and kill them.
Phase 1, Cell therapy, adult aml, mds
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials1
- Signals1
- Similar companies2